The North America Cell & Gene Therapy Manufacturing Services Market revenue is projected to witness exponential growth during 2020-2035. Supported by accelerating FDA approvals, investment flows, and expanding contract manufacturing capacities, the market is expected to rise from USD 1,600 Million in 2020 to over USD 8,300 Million by 2035. Key growth drivers include the advancement of personalized medicine and consistent investment in scalable manufacturing platforms to address rising demand across major therapeutic areas.
Oncology represents the dominant application area for cell and gene therapy manufacturing services in North America for 2025, reflecting the growing clinical pipeline and payer support for advanced cancer treatments. Cardiovascular diseases and rare disorders are gaining traction due to increased gene therapy approvals and the success of precision medicine initiatives. Neurological and infectious diseases continue to present growth opportunities, as new indications enter late-stage development following robust clinical results.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-cell-and-gene-therapy-manufacturing-services-market
Who are the key players in North America Cell & Gene Therapy Manufacturing Services Market industry?
The key players in the North America Cell & Gene Therapy Manufacturing Services Market include Lonza Group, Thermo Fisher Scientific, Catalent Inc., WuXi Advanced Therapies, and Charles River Laboratories. These companies offer comprehensive manufacturing solutions, leveraging advanced technologies and deep expertise to support the development and commercial production of cell and gene therapies.
What is the North America Cell & Gene Therapy Manufacturing Services Market growth?
The North America Cell & Gene Therapy Manufacturing Services Market is experiencing robust growth, driven by increasing FDA approvals and investment from players like Thermo Fisher Scientific. The market has seen double-digit annual growth rates recently, propelled by demand for scalable manufacturing solutions for novel therapies in oncology and rare diseases.
Which segment accounted for the largest North America Cell & Gene Therapy Manufacturing Services Market share?
The oncology segment accounts for the largest share of the North America Cell & Gene Therapy Manufacturing Services Market. High demand for personalized cancer treatments, including CAR-T cell therapies, and substantial investments from biopharmaceutical companies are underpinning segment dominance and fostering advancements in targeted cell and gene therapies for cancer.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com